natgillin/translations-raw huggingface dataset:
A process for preparing a crystalline compound Ia as defined in Claim 4, which comprises reacting compound B of the structure with a reducing agent that is an alkylsilyl hydride in the presence of an activating group that is as Lewis Acid to form compound I of the structure reacting compound I with (S)-propylene glycol, optionally adding seeds of compound Ia to the reaction mixture, in the presence of an organic solvent to form crystalline compound Ia 
Postupak za pripravu kristalnog spoja Ia kako je definirano u zahtjevu 4, naznačen time da se sastoji od reakcije spoja B sa strukturom sa redukcijskim sredstvom koje je alkilsilil hidrid u prisutnosti aktivirajuće skupine koja je kao Lewisova kiselina da se dobije spoj I sa strukturom reakcije spoja I sa (S)-propilen glikolom, uz proizvoljno dodavanje zametaka spoja Ia u reakcijsku smjesu, u prisutnosti organskog otapala da se dobije kristalni spoj Ia la, 15.
A compound represented by Formula I: 
Spoj kojeg prikazuje Formula I:
The use according to claim 17, wherein the cancer is selected from prostate cancer, non-small cell lung cancer, ovarian cancer, bladder cancer and gastric cancer. 
Uporaba prema zahtjevu 17, naznačena time da rak je odabran od raka prostate, raka pluća ne-malih stanica, raka jajnika, raka mjehura i raka želuca.
2,5-deoxyfructosazine, synthesised from glucosamine, was dissolved in Heineken® lager beer (0.5 g/L) and illuminated for 12 min. 
2,5-deoksifruktozazin, sintetiziran iz glukozamina, se otopi u Heineken" lager pivu (0,5 g/L) i osvjetljava 12 min.
A pharmaceutical composition comprising a compound of claim 1 and a therapeutically inert carrier. 
Farmaceutski sastav, naznačen time, da obuhvaća spoj prema bilo kojem od zahtjeva 1 do 8, te terapeutski inertan nosač.
A process according to claim 1, wherein the inert reaction medium is selected from the group consisting of diethyl ether, tetrahydrofuran, 2-methyltetrahydrofuran, tert-butyl-methylether, diisopropylether, and mixtures thereof. 
Postupak prema bilo kojem od zahtjeva 1 do 3, naznačen time da je inertni reakcijski medij u koraku (a) izabran iz skupine koja se sastoji od dietil etera, tetrahidrofurana, 2-metiltetrahidrofurana, terc-butil-metiletera, diizopropiletera ili bilo koje njihove smjese.
is selected from the group consisting of isopropyl, t-butyl and cyclopropyl; 
R, je izabran iz grupe koju čini izopropil, t-butil i ciklopropil;
LCMS are recorded on an Agilent 1100 LC system with a Waters Xterra MS C18 4.6 x 100 5 µM column, eluting with 5-95% 10 mM aqueous ammonium bicarbonate in acetonitrile over 10 minutes, with negative ion electrospray ionization or 5-95% water + 0.1 % TFA in acetonitrile with positive ion electrospray ionization. 
LCMS su zapisani na sistemu Agilent 1100 LC sa stupcem Waters Xterra MS C18 4,6 x 100 5 uM, ispirući s 5-95%-tnim 10 mM vodenim amonijevim bikarbonatom u aceto-nitrilu kroz 10 minuta, ionizacijom s negativnim ionskim elektrosprejem ili 5-95% vode + 0,1% TFA u acetonitrilu ionizacijom s pozitivnim ionskim elektrosprejem.
When initiating a steam-production operation, at the beginning the control means 35 as shown in Fig. 
Kada se započne proizvodnja vodeno pare, na početku sustav za kontrolu 35, kao što je prikazano na SI.
PTA-11267, and a light chain variable region consisting of the amino acid sequence of the light chain variable region of an antibody produced by a hybridoma deposited under ATCC Accession No. 
PTA-11267, te varijabilnu regiju lakog lanca koja se sastoji od sekvence amino kiseline varijabilne regije lakog lanca antitijela proizvedenog hibridomom koje je pohranjeno u Američkoj kolekciji tipova kulture (American Type Culture Collection - ATCC) Acesijski Br.
The formulation of claim 18, wherein said second polymeric material is based on the same polycarboxylic acid polymer as said third polymeric material, said the third polymeric material having a higher degree of neutralization than the second polymeric material. 
Formulacija lijeka s produljenim oslobađanjem za koju se traži zaštita patentom u bilo kojem od patentnih zahtjeva 1 do 3, pri čemu su drugi i treći polimerni materijal na bazi istog polimera polikarboksilne kiseline s trećim polimernim materijalom koji ima viši stupanj neutralizacije od drugog polimernog materijala.
An oral pharmaceutical formulation comprising a compound of formula (I): or salt or solvate thereof for use in the treatment of ocular neovascular disorders. 
Topikalna farmaceutska formulacija koja sadrži spoj formule (I): [image] ili njegovu sol ili solvat, naznačena time što je namijenjena upotrebi u liječenju neovaskularnih poremećaja oka izravnom primjenom u oko.
said RNAi agent is to be administered in an unbuffered solution, wherein preferably said unbuffered solution is saline or water; or 
navedeno RNAi sredstvo se treba primijeniti u nepuferiranoj otopini, pri čemu poželjno navedena nepuferirana otopina je fiziološka otopina ili voda; ili
The nucleic acid molecule of claims 1 or 2, wherein the expression by a prokaryotic promoter occurs in a bacteria cell. The nucleic acid molecule of claim 1 or 3, wherein the expression by a eukaryotic promoter occurs in a mammalian cell or a yeast cell. The nucleic acid molecule of claims 1, 3 or 5, wherein the mammalian cell is a CHO cell, 293 cell, or NSO cell. 
Molekula nukleinske kiseline prema patentnom zahtjevu 1 ili 2, naznačena time, da je VL povezan s oznakom te time, da je VH povezan s Fc. Molekula nukleinske kiseline prema patentnim zahtjevima od 1 do 3, naznačena time, da nukleinska kiselina kodira protein oblaganja koji se nalazi unutar sintetičkog introna, pri čemu je nukleinska kiselina smještena između nukleinske kiseline koja kodira CH1 i nukleinske kiseline koja kodira spojnicu-Fc ili Fc.
The type, number, and locant of the substituent(s) present in the structure are not particularly limited. When two or more substituents are present, they may be identical to or different from one another. Examples of the "substituent" include a halogen atom, a hydroxyl group, a cyano group, a nitro group, a C1-6 alkanoyl group, a C1-6 alkyl group, a C3-10 cycloalkyl group, a C2-6 alkenyl group, a C1-6 alkoxy group, an amino group, a C1-6 alkylamino group, a C1-6 alkanoylamino group, a C1-6 alkylaminocarbonyl group, a C1-6 alkylsulfonyl group, a C6-14 aromatic hydrocarbon group, a saturated or unsaturated heterocyclic group, a saturated or unsaturated heterocyclic-carbonyl group, and an oxo group. 
R* predstavlja atom vodika, po izboru supstituiranu C,4 alkil skupinu, po izboru supstituiranu C:.;9 cikloalkil skupinu, po izboru supstituiranu C4.;4 skupinu aromatskih ugljikovodika ili po izboru supstituiranu zasićenu ili nezasićenu heterocikličku skupinu, ili R! i R* mogu formirati, zajedno s atomom dušika na kojega su vezani, po izboru supstituirani heterociklički prsten koji sadrži dušik; pri čemu je supstituent od po izboru supstituiranih skupina ili struktura odabran iz skupine koja sadrži atom halogena, hidroksil skupinu, cijano skupinu, nitro skupinu, C;.4 alkanoil skupinu, Ci; g alkil skupinu, C3.10 Cikloalkil skupinu, C24 alkenil skupinu, C;4 alkoksi skupinu, amino skupinu, Cig alkilamino skupinu, C;.4 alkanoilamino skupinu, Cig alkilaminokarbonil skupinu, Cig alkilsulfonil skupinu C4.14 skupine aromatskih ugljikovodika, zasićene ili nezasićene heterocikličke skupine, zasićeni ili nezasićeni heterocikličke-karbonil skupine, te okso skupine;
The method according to claim 1 wherein m is 2 and n is 1; or a pharmaceutically acceptable salt thereof. 
Farmaceutski sastav, naznačen time, da obuhvaća spoj ili njegovu farmaceutski prihvatljivu sol prema zahtjevu 1 1 farmaceutski prihvatljiv nosač.
The method of any one of E1-E9, wherein the solid tumor is chosen from non-small cell lung cancer (NSCLC), renal cell carcinoma (RCC), melanoma, colorectal cancer, and serous ovarian carcinoma. The method of any one of E1-E10, wherein the anti-KIR antibody comprises 
Antitijela za primjenu iz bilo kojeg od patentnih zahtjeva 1-7, gdje rak je solidni tumor, ili naročito uznapredovali refraktorni solidni tumor, 1 po izboru je odabran od raka glave 1li vrata, nesitnostaničnog raka pluća (NSCLC), raka bubrežnih stanica (RCC), melanoma, kolorektalnog raka, i seroznog raka jajnika.
(a-2) the heavy chain variable domain depicted in SEQ ID NO:227 and the light chain variable domain depicted in SEQ ID NO:226; or 
varijabilna domena jakog lanca od SEQ ID NO:208 i varijabilna domena slabog lanca od SEQ ID NO:207; ili
Sustained release dosage forms are often attractive for the optimisation of therapy not only because the frequency of administration can be reduced, but also because of the reduction of fluctuations in the blood level. 
Oblici doziranja s produljenim otpuštanjem često su zanimljivi za optimizaciju terapije, ne samo zbog toga što se učestalost primjene može smanjiti, nego i zbog smanjenih fluktuacija razina u krvi.
a light chain having at least 90% sequence identity to the amino acid sequence of SEQ ID NO:87. 
slabi lanac koji ima identitet sekvence barem 90% od aminokiselinske sekvence od SEQ ID NO:87.
n, Z, Q, W, W1 and V are as defined in claim 9, and at least one of the Z groups and/or at least one of the Q groups are of the formula (IIa) or (IIb): 
(B) n, Z, Q, W, W! i V su u skladu s patentnim zahtjevom 9, a najmanje jedna od skupina Z i/ili najmanje jedna od skupina Q su formule (IIa) ili (IIb):
An antibody or antigen-binding fragment thereof, that specifically binds hIL-4R (SEQ ID NO: 1) with a KD of about 200 pM or less, as measured by surface plasmon resonance, comprising the CDRs from a HCVR and a LCVR sequence, wherein the HCVR/LCVR sequences are selected from SEQ ID NOs: 579/59 and 581/59. 
Antitijelo ili njegov fragment koji se veže na antigen, koje se specifično veže na hIL -4R (SEQ ID NO: 1) s konstantom KD od oko 200 pM ili manjom izmjereno površinskom plazmonskom rezonancijom, sadrži CDR iz HCVR i LCVR slijed, naznačen time, da su HCVR / LCVR sekvence odabrane iz SEQ ID NO: 579/59 i 581/59.
Another aspect of the disclosure is a pharmaceutical composition comprising a compound according to any one of paragraphs [0033]-[0137] and a pharmaceutically acceptable carrier. 
Farmaceutski sastav, naznačen time, da obuhvaća spoj prema zahtjevu 1 ili njegovu faramceutski prihvatljivu sol, te farmaceutski prihvatljiv nosač.
The organic phase was then diluted with N-methylpyrrolidinone (460 mL) was and the dichloromethane removed by stirring at 40° C. under vacuum for 2 hrs. 
Organsku fazu se zatim razrijedi N-metilpirolidinonom (460 ml), a diklormetan ukloni miješanjem 2 sata na 40 *C u vakuumu.
The ability of compounds of formula I to inhibit tumor growth in mice was tested as follow. 
Sposobnost spojeva formule I da inhibiraju rast tumora u miševa ispitana je kako slijedi.
According to one embodiment of the present invention, the cPCC has a specific surface area from 5.0 m2/g to 200.0 m2/g, preferably from 10.0 m2/g to 100.0 m2/g and most preferably from 15.0 m2/g to 50.0 m2/g, measured using nitrogen and the BET method. 
Upotreba u skladu s patentnim zahtjevom 1, naznačena time što cPCC ima specifičnu površinu od 5,0 m"/g do 200,0 m'/g, po mogućnosti od 10,0 m"/g do 100,0 m'/g, a najpoželjnije od 15,0 m?/g do 50,0 m/g, što je izmjereno uz pomoć dušika i postupkom BET.
Apomorphine may likewise preferably be used as an emetic in the abuse-proofing according to the invention, preferably in a quantity of preferably ≧3 mg, particularly preferably of ≧5 mg and very particularly preferably of ≧7 mg per administration unit. 
Isto tako pogodno može se kao emetik primijeniti apomorfin za osiguranje protiv zlouporabe prema izumu, prvenstveno u količini od prvenstveno 2-3 mg, osobito pogodno > 5 mg, a još pogodnije 2-7 mg po jedinici doziranja.
In one embodiment of the invention the compound of Formula V is mixed with the compound of Formula IV in a solvent, such as an alcohol, for example methanol or ethanol. 
U drugoj izvedbi ovoga izuma, spoj s formulom V je pomiješan sa spojem s formulom IV u otapalu, poput alkohola, na primjer _metanol ili etanol.
wherein: • the body is a solid plasma crucible of material which is lucent for exit of light therefrom, 
tijelo je kruta plazmena retorta (11) tvari koja je prozirna tako da propušta svjetlo koje iz njega izlazi, i
a retro-, an inverso- or a retro-inverso variant of the amino acid sequence of (a); or a pharmaceutically acceptable salt or solvate thereof. 
(b) retro-, inverzo- ili retro-inverzo varijantu sekvence aminokiseline pod a); ili njezinu farmaceutski prihvatljivu sol ili solvat.
The composition of any one of claims 1 to 6, wherein said CECs form a monolayer of uniformly sized cells with a predominantly hexagonal shape, and optionally wherein at least 50% of said CECs exhibit said hexagonal shape. 
Postupak prema zahtjevu 1, naznačen time što CEC tvore monosloj stanica jednake veličine, od kojih se barem 50 % pojavljuje u heksagonalnom obliku.
The upper edge 209 of the capsule 200 is in this way released, thereby allowing the whole passive part 150 to be removed from the machine with the aid of the handle 154 . 
Gornji rub 209 kapsule 200 se tako otpušta, omogućujući tako da se cijeli pasivni dio 150 ukloni iz stroja pomoću ručke 154.
Another embodiment of the present invention relates to the treatment of a sleep disorder. 
Upotreba spoja u skladu s patentnim zahtjevom 21, gdje poremećaj je poremećaj spavanja.
And alter 7 days a significant portion of the uncoated banana skin was brown spotted and less than 10% of the coated bananas had brown spots, which were very smal1 in comparison. 
I poslije 7 dana značajan dio kože neobloženih banana bio je prekriven smeđim točkama i manje od 10% obloženih banana je imalo smeđe točke, koje su bile vrlo sitne u usporedbi s onim kod neobloženih.
wherein the disease or condition is mucopolysaccharidosis I (MPS I); and wherein at least one digesting glycan enzyme is iduronidase. 
pri čemu bolest ili stanje je poremećaj MPS odabran iz skupine koju čine MPS IVA, MPS IVB i MPS VII;
A cured composition of nonwoven material comprising a nonwoven fiber and a cured binder wherein the cured composition is formed in a process comprising combining nonwoven fibers with the curable aqueous composition of any one of claims 1 to 11 to form a mixture and curing the mixture. 
Komponenta stvrdnjavanja netkanih materijala, koji sadrže netkana vlakna i vezivo za učvršćivanje, naznačena time, da je pripravak učvršćivanja nastao u procesu kombiniranja netkanih vlakana sa učvršćujućim vodenastim pripravkom iz bilo kojeg zahtjeva od 1 do 11, kako bi se dobila 1 učvrstila smjesa.
The compound according to claim 1, wherein E represents a phenyl group, a pyridin-2-yl, a cyclohexyl group, a pyrazol-1-yl group, a cyclopentyl group, an indol-4-yl group, a cyclopropyl group, a pyridin-3-yl group, an indol-3-yl group, a naphth-1-yl group, an imidazol-4-yl group or a pyridin-4-yl group. 
Spojevi u skladu s patentnim zahtjevom 1, naznačeni time, da E predstavlja fenilnu skupinu, piridin-2-il, cikloheksilnu skupinu, pirazol-1-il skupinu, ciklopentilnu skupinu, indol-4-il skupinu, ciklopropilnu skupinu, piridin-3-il skupinu, indol-3-il skupinu, naft-1-il skupinu, imidazol-4-il skupinu ili piridin-4-il skupinu.
Artificial contractile sphincter for control of urinary incontinence, comprising a structure adapted to be placed around the urethra, characterized in that the structure is designed to contract the urethra in at least two distinct regions in a pulsatory and alternately manner, and in that the structure is designed in such a way that the temperature of fluids or tissues surrounding the urethra does not increase above 40°C. 
Umjetni kontraktilni sfinkter za kontrolu urinarne inkontinencije, ima strukturu (1, 10, 20, 30, 50) prilagođenu tako da se postavi oko uretre i ima barem dva prolaza, naznačen time što su ti prolazi oblikovani da pritišću uretru na barem dva različita područja na pulsirajući i naizmjenični način i da prenose pritisak naizmjenično na svako područje uretre kroz period u rasponu od između 30 sekundi do 30 minuta, poželjno između 30 sekundi do 10 minuta i još poželjnije između 1 minute do 5 minuta, tako da se temperatura tekućina ili tkiva koji okružuju uretru ne poveća iznad 40°C.
The method according to any one of the preceding embodiments, wherein the number of oil droplets having a size of >1.2 µm in the second emulsion is 5 x 1010 /ml or less. 
Postupak prema bilo kojem zahtjevu od 1-3, naznačen time da broj uljnih kapljica koje imaju veličinu od >1.2 um u drugoj emulziji je 5 x 10/* /ml ili manje.
Use of a welded plastic container bag according to any one of claims 1-6 for collection and transport of bulk products, preferably for collection and transport of recyclable goods, more preferably for collection and transport of empty cans and bottles. 
Uporaba zavarene plastične vrećice za spremanje prema bilo kojem od zahtjeva 1-6, za prikupljanje i transport rasutih proizvoda, ponajprije za prikupljanje i transport robe koja se može reciklirati, poželjnije za skupljanje i prijevoz praznih limenki i boca.
By hinging open the parts 76, 77 about the hinge 78, the interior of the heat exchanger can be made accessible in a simple manner in order to clean this. 
Otvaranjem dijelova 76, 77 oko šarki 78, može se pristupiti na jednostavan način unutrašnjosti izmjenjivača topline, kako bi se očistio.
The first seat 9 communicates with a rear cavity 13, which is part of said guiding means of the axial position with respect to the sole 2, and which is provided, starting from the upper surface 10 of such sole, in the part which extends from the first seat 9 to the rear perimetral border of the sole 2; the cavity 13 is shaped, in transverse cross-section, substantially as having the general configuration of an inverted T, and has in top plan view approximately a rectangular shape, with a width and length advantageously less than those of the first seat 9. 
Prvi dosjed 9 povezan je sa stražnjim gnijezdom 13, koje je dio spomenutog sredstva za vođenje aksijalnog položaja u odnosu na potplat 2, 1 koje je postavljeno tako da započinje od gornje površine 10 potplata i ide prema dijelu koji idc od prvog dosjeda 9 do stražnjeg obodnog ruba potplata 2, dok je u poprečnom presjeku gnijezdo 13 oblikovano uglavnom tako da ima opću konfiguraciju obrnutog slova T, te gledano odozgo ima približno pravokutan oblik, sa širinom i duljinom koje su ponajprije manje od širine i duljine prvog dosjeda 9.
A bicontinuous micro-emulsion comprising a hydrophilic phase, a hydrophobic phase, a surface-active substance, and a catalyst absorbed in at least one of the hydrophilic phase and hydrophobic phase, which catalyst has been generated in situ in a precipitation reaction by reduction of a metal complex. The bicontinuous micro-emulsion according to claim 1, obtainable by mixing (i) a first bicontinuous micro-emulsion comprising a hydrophilic phase, a hydrophobic phase and a surface-active agent, to which bicontinuous micro-emulsion a salt or a metal complex of a catalyst material is supplied to the hydrophilic phase, and a (ii) second bicontinuous micro-emulsion comprising a hydrophilic phase, a hydrophobic phase and a surface-active agent, further containing a reducing material, wherein upon mixing a precipitation reaction takes place on which the catalyst is formed. 
Bikontinuirana mikroemulzija koja uključuje hidrofilnu fazu, hidrofobnu fazu 1 površinski reaktivnu supstancu; kao i katalizator u barem jednoj od hidrofilne faze i hidrofobne faze, koji je katalizator generiran in situ u reakciji taloženja redukcijom metalnog kompleksa, navedenu bikontinuiranu emulziju moguće je dobiti miješanjem (i) prve bikontinuirane mikroemulzije koja sadrži hidrofilnu fazu, hidrofobnu fazu i površinski aktivni agens, na koji bikontinuiranu emulziju se dovodi kompleks soli ili metala katalitičkog materijala u hidrofilnoj fazi, i (ii) drugu bikontinuiranu mikroemulziju koja sadrži hidrofilnu fazu, hidrofobnu fazu i površinski aktivni agens, nadalje sadrži reducirajući materijal, pri čemu miješanjem dolazi do reakcije taloženja u kojoj se formira katalizator.
A kit comprising a Hepatitis C virus NS3 protease inhibitor according to formula I and ritonavir. 
Komplet koji se sastoji od inhibitora proteaze NS3 hepatitisa virusa C u skladu s formulom I i ritonavirom.
The antibody of the invention, or a divalent functional fragment or derivative thereof, consists preferably of a human antibody. 
Antitijelo ili njegov dvovalentni funkcionalni fragment iz patentnih zahtjeva 1 do 6, za upotrebu kao lijek.
Pharmaceutical forms for the release of active compounds 
FARMACEUTSKI OBLICI ZA OSLOBAĐANJE AKTIVNIH SPOJEVA
The method according to claim 12, wherein the insertion site is located between two adjacent amino acids at a position between amino acids 570 and 611 of VP1 of AAV2 or the corresponding position in the capsid protein of another AAV serotype. 
Virion rAAV prema zahtjevu 7, naznačen time daje mjesto umetanja unutar amino kiselina 570-611 iz AAV2 kapsidnog proteina prikazanog u SEQ ID NO: 1, ili odgovarajuće mjesto u kapsidnom proteinu iz drugog AAV serotipa.
The said oil (3.0 g) was dissolved in dimethylformamide (10.5 ml) and formic acid (0.5 g) and at 5° zinc (0.7 g) was added. 
Spomenuto ulje (3,0 g) otopi se u dimetilformamidu (10,5 ml) i mravljoj kiselini (0,5 g) i doda se na 5? cink (0,7 g).
It may be in the form of a solvate, for example a hydrate, thereof, for example a pure enantiomer, a mixture of enatiomers, a racemate or a mixture thereof. 
Može biti u obliku njihovih solvata, na primjer hidrata, na primjer čisti enantiomer, smjesa enantiomera, racemat ili njihova smjesa.
The communication apparatus of claim 1, further comprising a client interface (112) adapted to communicate data from the event/data recorder to a remote computer (115) and to communicate commands from the remote computer to the EDR interface. 
Komunikacijski uređaj sukladno zahtjevu 1, naznačen time, da nadalje obuhvaća korisničko sučelje (112) prilagođen za prijenos podataka s uređajem za snimanje događaja/podataka na bežični predajnik (115) 1 za izdavanje naredbi od udaljenog računala na EDR sučelje.
The aqueous formulation of any of the foregoing claims comprising one or more excipients selected from a group comprising zinc, m-cresol, glycerol, polysorbate 20 and sodium, preferably comprising 90 µg/mL zinc, 2.7 mg/mL m-cresol and 20 mg/mL glycerol 85% or comprising 90 µg/mLzinc, 2.7 mg/mL m-cresol, 20 µg/mLpolysorbate 20 and 20 mg/mL glycerol 85%. 
Vodena formulacija prema zahtjevu 8 naznačena time da sadrži 90 µg/mL cinka, 2.7 mg/mL m-krezola i 20 mg/mL glicerola 85%. Vodena formulacija prema zahtjevu 8 naznačena time da sadrži 90 µg/mL cinka, 2.7 mg/mL m-krezola, 20 µg/mL polisorbata 20 i 20 mg/mL glicerola 85%.
This type is stronger and more often utilized for “heavy duty” operations such as fishing. 
Ova vrsta kabla je jača i mnogo češće korištena za teške uvjete rada, kao što je "pecanje",
A gel formulation having the following composition wt./wt.% is prepared: 1. 
Proizveden je pripravak gela koji ima slijedeći sastav wt./wt. %: 1.
a pharmaceutically acceptable fluid comprising about 90% polyethylene glycol and about 10% propylene glycol; and 
90% polietilen glikola i 10% propilen glikola; i ii) = tioglicerol u koncentraciji od 2.5 mg/mL.
wherein the at least one prediction unit is one among blocks including: a block equal in size to the coding unit; and a block among a plurality of blocks generated by equally dividing at least one of height and width of the coding unit, and 
kvantizirane koeficijente transformacije za najmanje jednu transformacijsku jedinicu generirane provođenjem inter predviđanja za barem jednu jedinicu predviđanja u jedinici za kodiranje radi generiranja predviđatelja i provođenje transformacije i kvantizacije na temelju predviđatelja i slike;
Detector Jasco UV-1575 Intelligent UV/VIS detector (or equivalent); 
Detektor Jasco UV-1577 Intelligent UV/VIS detektor (ili ekvivalent);